Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

boceprevir

Known as: 3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)-, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 
An orally bioavailable, synthetic tripeptide inhibitor of the nonstructural protein 3 and 4A complex (NS3/NS4A), with potential activity against… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
A novel coronavirus SARS-CoV-2, also called novel coronavirus 2019 (nCoV-19), started to circulate among humans around December… Expand
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2014
Highly Cited
2014
BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated… Expand
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
BACKGROUND Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2011
Highly Cited
2011
Background Peginterferon–ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV… Expand
Highly Cited
2011
Highly Cited
2011
BACKGROUND In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Highly Cited
2011
Highly Cited
2011
BACKGROUND Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2010
Highly Cited
2010
BACKGROUND Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients with… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2009
Highly Cited
2009
Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is currently being evaluated in… Expand
Review
2008
Review
2008
More than 170 million people worldwide are affected by the hepatitis C virus (HCV). The disease has been described as a "silent… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5